...
首页> 外文期刊>Clinical rheumatology >The efficacy of tramadol/acetaminophen combination tablets (Ultracet?) as add-on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti-inflammatory drug (NSAID)
【24h】

The efficacy of tramadol/acetaminophen combination tablets (Ultracet?) as add-on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti-inflammatory drug (NSAID)

机译:非甾体类抗炎药(NSAID)无法充分控制曲马多/对乙酰氨基酚联合片剂(Ultracet?)作为膝关节骨关节炎疼痛的附加和维持疗法的功效

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The purpose of this study is to compare the efficacy of tramadol 37.5 mg/acetaminophen 325 mg combination tablets (tramadol/APAP) with that of nonsteroidal anti-inflammatory drugs (NSAIDs) as maintenance therapy following tramadol/APAP and NSAID combination therapy in knee osteoarthritis (OA) pain which was inadequately controlled by NSAIDs. Subjects with knee OA for over 1 year and moderate pain (numerical rating scale [NRS] ≥5) despite at least 4 weeks' NSAID therapy (meloxicam 7.5 mg or 15 mg qd or aceclofenac 100 mg bid) received tramadol/APAP add-on (combination with NSAID) for 4 weeks. Thereafter, subjects with significant pain improvement (NRS <4) were randomized to receive either tramadol/APAP or NSAID for 8 weeks. On days 29 and 57, Western Ontario and McMaster Universities (WOMAC) OA index score was measured. Secondary measures included pain intensity (NRS), pain relief score, and subjects' and investigators' overall medication assessments. Of 143 subjects enrolled, 112 completed the 4-week tramadol/APAP and NSAID combination phase and 97 (67.8%) experienced significant pain improvement. Of the 97 subjects randomized, 36 in tramadol/APAP group and 47 in NSAID group completed the 8-week comparator study. On days 29 and 57, WOMAC scores and pain intensities did not increase in both groups compared to measurements immediately after the combination therapy. At these two time points, there were no significant differences in WOMAC scores, pain intensities, and other secondary measures between the two groups. Overall adverse event rates were similar in both groups. Tramadol/APAP add-on significantly improved knee OA pain which had been inadequately controlled by NSAIDs. In those subjects who showed favorable response to tramadol/APAP and NSAID combination therapy, both tramadol/APAP and NSAIDs were effective at maintaining the pain-reduced state and there was no significant difference in efficacy between tramadol/APAP and NSAIDs.
机译:这项研究的目的是比较曲马多/ APAP和NSAID联合治疗后曲马多37.5 mg /对乙酰氨基酚325 mg组合片剂(曲马多/ APAP)与非甾体抗炎药(NSAIDs)作为维持治疗的疗效(OA)疼痛,NSAIDs无法充分控制疼痛。尽管接受了至少4周的NSAID治疗(美洛昔康7.5 mg或15 mg qd或醋氯芬酸100 mg bid),但膝部OA超过1年且中度疼痛(数字评定量表[NRS]≥5)的受试者接受了曲马多/ APAP附加治疗(与NSAID组合)治疗4周。此后,将疼痛明显改善(NRS <4)的受试者随机分配接受曲马多/ APAP或NSAID治疗8周。在第29天和第57天,测量了安大略省西部和麦克马斯特大学(WOMAC)的OA指数得分。次要指标包括疼痛强度(NRS),疼痛缓解评分以及受试者和研究者的总体用药评估。在143名受试者中,有112名完成了为期4周的曲马多/ APAP和NSAID联合治疗阶段,其中97名(67.8%)的疼痛得到了明显改善。在随机分配的97位受试者中,曲马多/ APAP组36位和NSAID组47位完成了为期8周的比较研究。与联合治疗后立即进行的测量相比,在第29天和第57天,两组的WOMAC评分和疼痛强度均未增加。在这两个时间点上,两组之间的WOMAC评分,疼痛强度和其他次要措施之间无显着差异。两组的总体不良事件发生率相似。曲马多/ APAP附加剂可显着改善NSAIDs无法充分控制的膝骨OA疼痛。在对曲马多/ APAP和NSAID联合治疗表现出良好反应的受试者中,曲马多/ APAP和NSAID均可有效维持减轻疼痛的状态,曲马多/ APAP和NSAID的疗效无显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号